Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia

Ninety percent of relapse/refractory B‐cell acute lymphatic leukemia (R/R B‐ALL) patients can achieve complete remission (CR) after CD19‐targeting chimeric antigen receptor T (CAR‐T) cell therapy. However, around 50% of them relapse in 1 year. Persistent CAR‐T cell engraftment is considered as the k...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Futian, Ho, Jin‐Yuan, Du, Huan, Xuan, Fan, Wu, Xiaoli, Wang, Qinglong, Wang, Lin, Liu, Ying, Ba, Min, Wang, Yizhuo, Luo, Jianmin, Li, Jianqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973049/
https://www.ncbi.nlm.nih.gov/pubmed/31465532
http://dx.doi.org/10.1002/hon.2672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973049/
https://www.ncbi.nlm.nih.gov/pubmed/31465532
http://dx.doi.org/10.1002/hon.2672

Ejemplares similares